Advertisement

Urine proteomic profiling in patients with nephrolithiasis and cystinuria

  • Larisa Kovacevic
  • Joseph A. Caruso
  • Hong Lu
  • Natalija Kovacevic
  • Yegappan Lakshmanan
  • Nicholas J. Carruthers
  • David S. Goldfarb
Urology - Original article

Abstract

Purpose

The purpose of the study was to assess the differences in the concentration and function of urinary proteins between patients with cystine stones (CYS) and healthy controls (HC). We postulated that CYS and HC groups would demonstrate different proteomic profiles.

Methods

A pilot study was performed comparing urinary proteomes of 10 patients with CYS and 10 age- and gender-matched HC, using liquid chromatography-mass spectrometry. Proteins which met the selection criteria (i) ≥ 2 unique peptide identifications; (ii) ≥ twofold difference in protein abundance; and (iii) ≤ 0.05 p value for the Fisher’s Exact Test were analyzed using Gene Ontology classifications.

Results

Of the 2097 proteins identified by proteomic analysis, 398 proteins were significantly different between CYS and HC. Of those, 191 were involved in transport processes and 61 in inflammatory responses. The majority were vesicle-mediated transport proteins (78.5%), and 1/3 of them were down-regulated; of those, 12 proteins were involved in endosomal transport (including 6 charged multivesicular body proteins (CHMP) and 3 vacuolar sorting-associated proteins) and 9 in transmembrane transport. Myosin-2 and two actin-related proteins were significantly up-regulated in the vesicle-mediated transport group.

Conclusion

We provide proteomic evidence of impaired endocytosis, dysregulation of actin and myosin cytoskeleton, and inflammation in CYS. Endosomal transport proteins were down-regulated mainly through defective CHMP. These findings may contribute to further understanding of the pathogenesis of CYS, potentially affecting its management.

Keywords

Nephrolithiasis Cystinuria Urine Proteomics 

Notes

Funding

This study was funded by the Rare Kidney Stone Consortium (5U54DK083908-05), a part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences’ (NCATS). This consortium is funded through a collaboration between NCATS, and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The Wayne State University Proteomics Core is supported through the NIH Center Grant P30 ES 020957, the NIH Cancer Center Support Grant P30 CA 022453 and the NIH Shared Instrumentation Grant S10 OD 010700. We are thankful to Frank Modersitzki for his help with urine specimen collection and processing and with data collection.

Compliance with ethical standards

Conflict of interest

D.S. Goldfarb is a consultant for Retrophin and is owner of Ravine Group. The rest of the authors have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

The urine was obtained for routine urinalysis for clinical care, and would have then been discarded; it was sent to the proteomics laboratory without any personal health identification information. Under these circumstances, analysis of the urine is not considered human subjects research. and therefore informed consent was not required from the participants included in the study.

Supplementary material

11255_2018_2044_MOESM1_ESM.docx (794 kb)
Supplementary material 1 (DOCX 794 KB)

References

  1. 1.
    Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, Palacín M (2010) Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 6(7):424–424CrossRefPubMedGoogle Scholar
  2. 2.
    Pras E, Arber N, Aksentijevich I, Katz G, Schapiro JM, Prosen L, Gruberg L, Harel D, Liberman U, Weissenbach J (1994) Localization of a gene causing cystinuria to chromosome 2p. Nat Genet 6(4):415–419CrossRefPubMedGoogle Scholar
  3. 3.
    Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P (2005) Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol 20:19–24CrossRefPubMedGoogle Scholar
  4. 4.
    Dahlberg PJ, Van den Berg CJ, Kurtz SB, Wilson DM, Smith LH (1977) Clinical features and management of cystinuria. Mayo Clin Proc 52:533–542PubMedGoogle Scholar
  5. 5.
    Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ (2002) The impact of cystinuria on renal function. J Urol 168:27–20CrossRefPubMedGoogle Scholar
  6. 6.
    Thongboonkerd V (2008) Proteomics and kidney stone disease. Contrib Nephrol 160:142–148CrossRefPubMedGoogle Scholar
  7. 7.
    Cadieux PA, Beiko DT, Watterson JD, Burton JP, Howard JC, Knudsen BE, Gan BS, McCormick JK, Chambers AF, Denstedt JD, Reid G (2004) Surface- enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS): a new proteomic urinary test for patients with urolithiasis. J Clin Lab Anal 18(3):170–175CrossRefPubMedGoogle Scholar
  8. 8.
    Thongboonkerd V (2007) Practical points in urinary proteomics. J Proteome Res 6(10):3881–3880CrossRefPubMedGoogle Scholar
  9. 9.
    Piper RC, Katzmann DJ (2007) Biogenesis and function of multivesicular bodies. Annu Rev Cell Dev Biol 23:519–547CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Eshbach ML, Weisz OA (2017) Receptor-mediated endocytosis in the proximal tubule. Annu Rev Physiol 79:425–448CrossRefPubMedGoogle Scholar
  11. 11.
    Bagga HS, Chi T, Miller J, Stoller ML (2013) New insights into the pathogenesis of renal calculi. Urol Clin N Am 40(1):1–12CrossRefGoogle Scholar
  12. 12.
    Evan AP, Coe FL, Lingeman JE, Shao Y, Matlaga BR, Kim SC, Bledsoe SB, Sommer AJ, Grynpas M, Phillips CL, Worcester EM (2006) Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int 69(12):2227–2235CrossRefPubMedGoogle Scholar
  13. 13.
    Sabharanjak S, Sharma P, Parton RG (2002) GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independeent pinocytic pathway. Dev Cell 2:411–423CrossRefPubMedGoogle Scholar
  14. 14.
    Kovacevic L, Lu H, Caruso JA, Lakshmanan Y (2016) Renal tubular dysfunction in pediatric urolithiasis: proteomic evidence. Urology 92:100–105CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Brooks ER, Hoppe B, Milliner DS, Salido E, Rim J, Krevitt LM, Olson JB, Price HE, Vural G, Langman CB (2016) Assessment of urine proteomics in type 1 primary hyperoxaluria. Am J Nephrol 43(4):293–303CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nagamori S, Wiriyasermkul P, Guarch ME, Okuyama H, Nakagomi S, Tadagaki K, Nishinaka Y, Bodoy S, Takafuji K, Okuda S, Kurokawa J, Ohgaki R, Nunes V, Palacín M, Kanai Y (2016) Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci USA 113(3):775–780CrossRefPubMedGoogle Scholar
  17. 17.
    Bourderioux M, Nguyen-Khoa T, Chhuon C, Jeanson L, Tondelier D, Walczak M, Ollero M, Bekri S, Knebelmann B, Escudier E, Escudier B, Edelman A, Guerrera IC (2014) A new workflow for proteomic analysis of urinary exosomes and assessment in cystinuria patients. J Proteome Res 14(1):567–777CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Larisa Kovacevic
    • 1
  • Joseph A. Caruso
    • 2
  • Hong Lu
    • 1
  • Natalija Kovacevic
    • 1
    • 3
  • Yegappan Lakshmanan
    • 1
  • Nicholas J. Carruthers
    • 2
  • David S. Goldfarb
    • 4
  1. 1.Department of Pediatric UrologyChildren’s Hospital of MichiganDetroitUSA
  2. 2.Institute of Environmental Health SciencesWayne State UniversityDetroitUSA
  3. 3.Vattikuti Urology InstituteHenri Ford HospitalDetroitUSA
  4. 4.Nephrology DivisionNew York University Langone Medical CenterNew YorkUSA

Personalised recommendations